azacitidine has been researched along with Waldenstrom Macroglobulinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, H; Hirano, M; Ikegami, M; Inoue, N; Ishihara, Y; Maruyama, D; Mishima, Y; Nishimura, N; Onda, N; Shirouchi, Y; Takeuchi, K; Tamba, M | 1 |
| Egle, A; Greil, R; Kemmerling, R; Melchardt, T; Moshir, S; Neureiter, D; Pleyer, L; Weiss, L | 1 |
2 other study(ies) available for azacitidine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Durable response of therapy-related MDS/AML with concomitant Waldenström's macroglobulinemia treated with venetoclax and azacitidine.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Waldenstrom Macroglobulinemia | 2022 |
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Humans; Male; Remission Induction; Rituximab; Waldenstrom Macroglobulinemia | 2011 |